Citations

Clear

439 citation(s) found for "Stone, M".

ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs)
Dubner, Sérgio , Steinberg, Jonathan S. , Stone, Peter H. , Brugada, Josép , Piotrowicz, Ryszard , Hayes, David L. , Kirchhof, Paulus , Zaręba, Wojciech , Schuger, Claudio , Aktaş, Mehmet K. , Chudzik, Michał , Israel, Carsten, Padeletti, Luigi, (Italy), Michele Brignole, Brignole, Michele , Auricchio, Angelo , Vardas, Panos , Breithardt, Günter , Mittal, Suneet , Varma, Niraj , Kirchhof, Paulus , Zareba, Wojciech

Mayo Clinic

Europace | January 10, 2012 | Volume: 14 | Issue: 2 | Pages: 278-293

10.1093/europace/eur303 | PMID 22232544 Get It

Abstract We are in the midst of a rapidly evolving era of technology-assisted medicine. The field of telemedicine provides the opportunity for highly individualized medical management in a way that has never been possible before. Evolving medical technologies using cardiac implantable devices (CIEDs) with capabilities for remote monitoring permit evaluation of multiple parameters of cardiovascular physiology and risk, including cardiac rhythm, device function, blood pressure values, the presence of myocardial ischaemia, and the degree of compensation of congestive heart failure. Cardiac risk, device status, and response to therapies can now be assessed with these electronic systems of detection and reporting. This document reflects the extensive experience from investigators and innovators around the world who are shaping the evolution of this rapidly expanding field, focusing in particular on implantable pacemakers (IPGs), implantable cardioverter-defibrillators (ICDs), devices for cardiac resynchronization therapy (CRT) (both, with and without defibrillation properties), loop recorders, and haemodynamic monitoring devices. This document covers the basic methodologies, guidelines for their use, experience with existing applications, and the legal and reimbursement aspects associated with their use. To adequately cover this important emerging topic, the International Society for Holter and Noninvasive Electrocardiology (ISHNE) and the European Heart Rhythm Association (EHRA) combined their expertise in this field. We hope that the development of this field can contribute to improve care of our cardiovascular patients.
IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis
Kelley, James, Monach, Paul A. , Ji, Chuanyi, Zhou, Yebin , Wu, Jianming , Tanaka, Sumiaki, Mahr, Alfred , Johnson, Sharleen P , McAlear, Carol A. , Cuthbertson, David , Carette, Simon , Davis, John C. , Dellaripa, Paul F. , Hoffman, Gary S., Langford, Carol A. , Seo, Philip , Clair, E. William St. , Stone, John H., Ytterberg, Steven R. , Edberg, Jeffrey C., Kimberly, Robert P. , Khalidi, Nader , Specks, Ulrich , Spiera, Robert , Merkel, Peter A. , Mahr, Alfred , Monach, Paul A

Mayo Clinic

Proceedings of the National Academy of Sciences | December 7, 2011 | Volume: 108 | Issue: 51 | Pages: 20736-20741

10.1073/pnas.1109227109 | PMID 22147912 Get It

Granulomatosis with polyangiitis (Wegener's) is a rare autoimmune neutrophil-mediated vasculitis that can cause renal disease and mucosal manifestations. Antineutrophil cytoplasmic antibodies (ANCA) are present in many patients, vary in level over time, and induce neutrophil activation through engagement with Fc receptors (FcRs). Given roles for FcRs in ANCA-mediated neutrophil activation and IgA antibodies in mucosal immunity, we hypothesized that FcR genetics and previously unappreciated IgA ANCA affect clinical presentation. We assembled a total of 673 patients and 413 controls from two multicenter cohorts, performed ELISA and immunofluorescence assays to determine IgA and IgG ANCA positivity, and used Illumina, TaqMan, or Pyrosequencing to genotype eight haplotype-tagging SNPs in the IgA FcR ( FCAR ) and to determine NA1/NA2 genotype of FCGR3B, the most prevalent neutrophil IgG FcR. We evaluated neutrophil activation by measuring degranulation marker CD11b with flow cytometry or neutrophil extracellcular trap formation with confocal microscopy. Functional polymorphisms in FCGR3B and FCAR differed between patient groups stratified by renal involvement. IgA ANCA were found in ∼30% of patients and were less common in patients with severe renal disease. Neutrophil stimulation by IgA or IgG ANCA led to degranulation and neutrophil extracellcular trap formation in a FcR allele-specific manner (IgA:FCAR P = 0.008; IgG:FCGR3B P = 0.003). When stimulated with IgA and IgG ANCA together, IgG ANCA induced neutrophil activation was reduced ( P = 0.0001). FcR genotypes, IgA ANCA, and IgG ANCA are potential prognostic and therapeutic targets for understanding the pathogenesis and presentation of granulomatosis with polyangiitis (Wegener's).
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Wang, Eunice S. , Baer, Maria R. , Perl, Alexander E. , Coutré, Steven , Stuart, Robert K. , Baccarani, Michele , Cripe, Larry D., Tallman, Martin S. , Meloni, Giovanna, Godley, Lucy A. , Langston, Amelia , Amadori, Sergio , Lewis, Ian D., Nagler, Arnon , Stone, Richard M. , Yee, Karen , Douer, Dan , Wiktor-Jędrzejczak, W , Juliusson, Gunnar , Litzow, Mark R. , Petersdorf, Stephen H., Sanz, Miguel Á. , Kantarjian, Hagop M. , Tremmel, Lothar, Bensen-Kennedy, Debra M., Small, Donald , Levis, Mark J. , Ravandi, Farhad , Wang, Eunice S. , Erba, Harry Paul , Advani, Anjali S. , Sato, Takashi , Smith, B. Douglas , Godley, Lucy A , Kantarjian, Hagop

Mayo Clinic

Blood | January 26, 2011 | Volume: 117 | Issue: 12 | Pages: 3294-3301

10.1182/blood-2010-08-301796 | PMID 21270442 Get It

Abstract In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of the FLT3 inhibitor lestaurtinib twice daily. Endpoints included complete remission or complete remission with incomplete platelet recovery (CR/CRp), overall survival, safety, and tolerability. Correlative studies included pharmacokinetics and analysis of in vivo FLT3 inhibition. There were 29 patients with CR/CRp in the lestaurtinib arm and 23 in the control arm (26% vs 21%; P = .35), and no difference in overall survival between the 2 arms. There was evidence of toxicity in the lestaurtinib-treated patients, particularly those with plasma levels in excess of 20μM. In the lestaurtinib arm, FLT3 inhibition was highly correlated with remission rate, but target inhibition on day 15 was achieved in only 58% of patients receiving lestaurtinib. Given that such a small proportion of patients on this trial achieved sustained FLT3 inhibition in vivo, any conclusions regarding the efficacy of combining FLT3 inhibition with chemotherapy are limited. Overall, lestaurtinib treatment after chemotherapy did not increase response rates or prolong survival of patients with FLT3 mutant acute myeloid leukemia in first relapse. This study is registered at www.clinicaltrials.gov as #NCT00079482.
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, Animesh , Jamieson, Catriona , Cortes, Jörge E. , Talpaz, Moshe , Stone, Richard M. , Silverman, Michael H. , Gilliland, D. Gary, Shorr, Jolene, Tefferi, Ayalew , Gotlib, Jason , Cortes, Jorge , Talpaz, Moshe

Mayo Clinic

Journal of Clinical Oncology | January 11, 2011 | Volume: 29 | Issue: 7 | Pages: 789-796

10.1200/jco.2010.32.8021 | PMID 21220608 Get It

Purpose Myelofibrosis is a myeloid malignancy associated with anemia, splenomegaly, and constitutional symptoms. Patients frequently harbor JAK-STAT activating mutations that are sensitive to TG101348, a selective small-molecule Janus kinase 2 (JAK2) inhibitor. Patients and Methods In a multicenter phase I trial, oral TG101348 was administered once a day to patients with high- or intermediate-risk primary or post–polycythemia vera/essential thrombocythemia myelofibrosis. Results Fifty-nine patients were treated, including 28 in the dose-escalation phase. The maximum-tolerated dose was 680 mg/d, and dose-limiting toxicity was a reversible and asymptomatic increase in the serum amylase level. Forty-three patients (73%) continued treatment beyond six cycles; the median cumulative exposure to TG101348 was 380 days. Adverse events included nausea, vomiting, diarrhea, anemia, and thrombocytopenia; corresponding grades 3 to 4 incidence rates were 3%, 3%, 10%, 35%, and 24%. TG101348 treatment had modest effect on serum cytokine levels, but greater than half of the patients with early satiety, night sweats, fatigue, pruritus, and cough achieved rapid and durable improvement in these symptoms. By six and 12 cycles of treatment, 39% and 47% of patients, respectively, had achieved a spleen response per International Working Group criteria. The majority of patients with leukocytosis or thrombocytosis at baseline (n = 28 and n = 10, respectively) achieved normalization of blood counts after six (57% and 90%, respectively) and 12 (56% and 88%, respectively) cycles. A significant decrease in JAK2 V617F allele burden was observed at 6 months in mutation-positive patients (n = 51; P = .04), particularly in the subgroup with allele burden greater than 20% (n = 23; P < .01); the decrease was durable at 12 months. Conclusion TG101348 is well tolerated and produces significant reduction in disease burden and durable clinical benefit in patients with myelofibrosis.
Shock Wave Lithotripsy is Not Predictive of Hypertension Among Community Stone Formers at Long-Term Followup
Krambeck, Amy E. , Li, Xujian, Bergstralh, Eric J., Gettman, Matthew T., Rule, Andrew D. , Lieske, John C.

Mayo Clinic

Journal of Urology | November 14, 2010 | Volume: 185 | Issue: 1 | Pages: 164-169

10.1016/j.juro.2010.09.033 | PMID 21074794 Get It

Percutaneous Nephrolithotomy for a 2,8-Dihydroxyadenine Stone in a Horseshoe Kidney
Mitchell, Christopher , Leiske, John, Krambeck, Amy E. , Williams, James C. , Cornell, Lynn D.

Mayo Clinic

Videourology™ | October 18, 2010 | Volume: 24 | Issue: 5 | Pages: No page available

10.1089/vid.2010.0114 Get It

SAGE-Journals-Accessible-Video-Player 10.1089/vid.2010.0114.M1 sj-vid-1-vid-10.1089_vid.2010.0114
Contralateral Ureteroscopy Performed at Percutaneous Nephrolithotomy: A Unique Evaluation of Stone-Free Rates
Wirtz, Patrick, Krambeck, Amy E. , Handa, Shelly E., Terry, Colin, Lingeman, James E.

Mayo Clinic

Journal of Urology | October 17, 2010 | Volume: 184 | Issue: 6 | Pages: 2378-2382

10.1016/j.juro.2010.08.029 | PMID 20952007 Get It

Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein
Liu, Yan , Mo, Lan , Goldfarb, David S. , Evan, Andrew P., Liang, Feng‐Xia , Khan, Saeed R. , Wu, Xue‐Ru , Lieske, John C. , Goldfarb, David S

Mayo Clinic

American Journal of Physiology-Renal Physiology | July 12, 2010 | Volume: 299 | Issue: 3 | Pages: F469-F478

10.1152/ajprenal.00243.2010 | PMID 20591941 Get It

Mammalian urine contains a range of macromolecule proteins that play critical roles in renal stone formation, among which Tamm-Horsfall protein (THP) is by far the most abundant. While THP is a potent inhibitor of crystal aggregation in vitro and its ablation in vivo predisposes one of the two existing mouse models to spontaneous intrarenal calcium crystallization, key controversies remain regarding the role of THP in nephrolithiasis. By carrying out a long-range follow-up of more than 250 THP-null mice and their wild-type controls, we demonstrate here that renal calcification is a highly consistent phenotype of the THP-null mice that is age and partially gene dosage dependent, but is gender and genetic background independent. Renal calcification in THP-null mice is progressive, and by 15 mo over 85% of all the THP-null mice develop spontaneous intrarenal crystals. The crystals consist primarily of calcium phosphate in the form of hydroxyapatite, are located more frequently in the interstitial space of the renal papillae than intratubularly, particularly in older animals, and lack accompanying inflammatory cell infiltration. The interstitial deposits of hydroxyapatite observed in THP-null mice bear strong resemblances to the renal crystals found in human kidneys bearing idiopathic calcium oxalate stones. Compared with 24-h urine from the wild-type mice, that of THP-null mice is supersaturated with brushite (calcium phosphate), a stone precursor, and has reduced urinary excretion of citrate, a stone inhibitor. While less frequent than renal calcinosis, renal pelvic and ureteral stones and hydronephrosis occur in the aged THP-null mice. These results provide direct in vivo evidence indicating that normal THP plays an important role in defending the urinary system against calcification and suggest that reduced expression and/or decreased function of THP could contribute to nephrolithiasis.
Incidence of Highly Important Extravascular Findings Detected on CT Angiography of the Abdominal Aorta and the Lower Extremities
Naidu, Sailen G., Hara, Amy K., Brandis, Aaron R., Stone, William M., Naidu, Sailendra

Mayo Clinic

American Journal of Roentgenology | May 20, 2010 | Volume: 194 | Issue: 6 | Pages: 1630-1634

10.2214/ajr.09.3538 | PMID 20489106 Get It

Reperfusion Injury, Microvascular Dysfunction, and Cardioprotection
Prasad, Abhiram , Stone, Gregg W. , Holmes, David R. , Gersh, Bernard J. , Prasad, Abhiram

Mayo Clinic

Circulation | November 23, 2009 | Volume: 120 | Issue: 21 | Pages: 2105-2112

10.1161/circulationaha.108.814640 | PMID 19933949 Get It